Bastion Asset Management Inc. Invests $2.40 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

Bastion Asset Management Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 38,336 shares of the company's stock, valued at approximately $2,398,000. TransMedics Group comprises about 1.6% of Bastion Asset Management Inc.'s investment portfolio, making the stock its 27th biggest position. Bastion Asset Management Inc. owned about 0.11% of TransMedics Group at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clear Creek Financial Management LLC acquired a new position in TransMedics Group during the fourth quarter worth $352,000. Vaughan Nelson Investment Management L.P. grew its holdings in TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after purchasing an additional 32,605 shares during the period. Baillie Gifford & Co. grew its holdings in TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after purchasing an additional 34,947 shares during the period. State of Michigan Retirement System bought a new stake in TransMedics Group in the fourth quarter valued at approximately $6,734,000. Finally, Peregrine Capital Management LLC raised its stake in TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after buying an additional 25,814 shares during the period. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Piper Sandler reissued an "overweight" rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a report on Friday. Canaccord Genuity Group restated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer upped their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded up $20.11 during mid-day trading on Friday, reaching $113.31. The company had a trading volume of 3,795,109 shares, compared to its average volume of 1,341,812. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The business's 50-day simple moving average is $77.68 and its 200 day simple moving average is $75.80. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of 120.54 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same quarter last year, the business posted $0.35 EPS. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. On average, research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.